Join
Live feed
·
PRReleasevia Quantisnow
Kairos Pharma Ltd. logo

Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer

ByQuantisnow·Wall Street's wire, on your screen.
KAPA· Kairos Pharma Ltd.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track KAPA (Kairos Pharma Ltd.) and more on Quantisnow.